NCT01537107 arm group e9160e94a4a6d1bbe5ca9f711f7366a2 [clinicaltrials_resource:NCT01537107/arm-group/e9160e94a4a6d1bbe5ca9f711f7366a2]
pharmacological study [clinicaltrials_resource:05580ce34a0759077133039c1db3639c]sirolimus [clinicaltrials_resource:3d4b7f060fae6cf0c8354bbd9768bc52]laboratory biomarker analysis [clinicaltrials_resource:80e817ff5c3ab5668819cd42829a6f7e]vismodegib [clinicaltrials_resource:9c354be8407e24e46b05c1f075d609e4]computed tomography [clinicaltrials_resource:a0a055a62e87a0b86bff2b1f3d00f91f]positron emission tomography [clinicaltrials_resource:dd0625e6fbbf3db28811c005aa3af37b]fludeoxyglucose F 18 [clinicaltrials_resource:f7c33f96e31c0310e44fd292d50cc8f1]Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery [clinicaltrials:NCT01537107]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01537107 arm group e9160e94a4a6d1bbe5ca9f711f7366a2 [clinicaltrials_resource:NCT01537107/arm-group/e9160e94a4a6d1bbe5ca9f711f7366a2]
Bio2RDF identifier
NCT01537107/arm-group/e9160e94a4a6d1bbe5ca9f711f7366a2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 160e94a4a6d1bbe5ca9f711f7366a2
description [clinicaltrials_vocabulary:description]
Patients receive sirolimus PO ...... sion or unacceptable toxicity.
identifier
clinicaltrials_resource:NCT01537107/arm-group/e9160e94a4a6d1bbe5ca9f711f7366a2
title
NCT01537107 arm group e9160e94a4a6d1bbe5ca9f711f7366a2
@en
type
label
NCT01537107 arm group e9160e94 ...... 60e94a4a6d1bbe5ca9f711f7366a2]
@en